AIM: To study the serum concentration of IL-1beta, IL-1 receptor antagonist (IL-1Ra) and IL-18 in Galphai2-deficient mice at the age of 6 (healthy), 12 (pre-colitic) and 24 wk (colitic) and in healthy control mice. METHODS: At the time of killing, serum samples were collected and IL-1beta, IL-1Ra and IL-18 levels were measured using enzyme-linked immunosorbent assays. RESULTS: Serum concentration of IL-1Ra was significantly increased in pre-colitic (median: 524 ng/L; P=0.02) and colitic (450 ng/L; P=0.01), but not in healthy (196 ng/L) Galphai2-deficient mice as compared with controls (217 ng/L). Serum concentrations of IL-1beta did not differ between Galphai2-deficient mice and their controls, irrespective of age, IL-18 was significantly increased in colitic, but not in pre-colitic mice compared with controls (510 ng/L vs 190 ng/L; P=0.05). CONCLUSION: The increased serum concentrations of IL-18 and IL-1Ra in established diseases are suggested as markers of ongoing colitis. Interestingly, the significantly increased serum concentration of IL-1Ra in pre-colitic mice is found to be an early marker of disease progression.
AIM: To study the serum concentration of IL-1beta, IL-1 receptor antagonist (IL-1Ra) and IL-18 in Galphai2-deficient mice at the age of 6 (healthy), 12 (pre-colitic) and 24 wk (colitic) and in healthy control mice. METHODS: At the time of killing, serum samples were collected and IL-1beta, IL-1Ra and IL-18 levels were measured using enzyme-linked immunosorbent assays. RESULTS: Serum concentration of IL-1Ra was significantly increased in pre-colitic (median: 524 ng/L; P=0.02) and colitic (450 ng/L; P=0.01), but not in healthy (196 ng/L) Galphai2-deficient mice as compared with controls (217 ng/L). Serum concentrations of IL-1beta did not differ between Galphai2-deficient mice and their controls, irrespective of age, IL-18 was significantly increased in colitic, but not in pre-colitic mice compared with controls (510 ng/L vs 190 ng/L; P=0.05). CONCLUSION: The increased serum concentrations of IL-18 and IL-1Ra in established diseases are suggested as markers of ongoing colitis. Interestingly, the significantly increased serum concentration of IL-1Ra in pre-colitic mice is found to be an early marker of disease progression.
Authors: G Monteleone; F Trapasso; T Parrello; L Biancone; A Stella; R Iuliano; F Luzza; A Fusco; F Pallone Journal: J Immunol Date: 1999-07-01 Impact factor: 5.422
Authors: T Kanai; M Watanabe; A Okazawa; T Sato; M Yamazaki; S Okamoto; H Ishii; T Totsuka; R Iiyama; R Okamoto; M Ikeda; M Kurimoto; K Takeda; S Akira; T Hibi Journal: Gastroenterology Date: 2001-10 Impact factor: 22.682
Authors: Andrei E Medvedev; Arnd Lentschat; Larry M Wahl; Douglas T Golenbock; Stefanie N Vogel Journal: J Immunol Date: 2002-11-01 Impact factor: 5.422
Authors: Kristina Elgbratt; Malin Bjursten; Roger Willén; Paul W Bland; Elisabeth Hultgren Hörnquist Journal: Immunology Date: 2007-05-09 Impact factor: 7.397
Authors: Rana Al-Sadi; Shuhong Guo; Dongmei Ye; Karol Dokladny; Tarik Alhmoud; Lisa Ereifej; Hamid M Said; Thomas Y Ma Journal: J Immunol Date: 2013-05-08 Impact factor: 5.422